MedTrace Logo

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

NCT06939452 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-04-07

No results posted yet for this study

Summary

To evaluate the efficacy and safety of anlotinib combined with TQB2450 and the SOX regimen as first-line treatment for advanced gastric cancer with low PD-L1 expression

Conditions

  • Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Interventions

DRUG

anlotinib +TQB2450 + Oxaliplatin+S-1

Anlotinib: 10mg, po, d1-14,q3w,until disease progression or unacceptable toxicity. TQB2450: 1200mg, iv, d1, q3w,until disease progression or unacceptable toxicity. Oxaliplatin: 130mg/㎡, iv, d1,6 cycles. S-1:40mg, po, bid, d1\~14,6 cycles.

Sponsors & Collaborators

  • Yongxu Jia

    lead OTHER

Principal Investigators

  • Yongxu Jia · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-07
Primary Completion
2026-06-01
Completion
2026-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06939452 on ClinicalTrials.gov